Study Group: Forensic Psychiatrists (US)(?)
Council Members in this Study Group: 95
Request a survey with this Study Group
Leading Experts in this Study Group
Psychiatrist
North Scottsdale Psychiatric Specialists
Robert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and the treatment...
President
Red Oak Psychiatry Associates, P. A.
Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Psychiatrists (US) | 1126 |
| Psychiatrists | 1474 |
| Physicians who Treat ADHD (US) | 439 |
| Physicians who Treat Schizophrenia (US) | 351 |
| Physicians who Treat Depression (US) | 384 |
| Effexor XR Prescribers (US) | 141 |
| Child and Adolescent Psychiatrists (US) | 177 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
1. Iloperidone has demonstrated efficacy in treating positive and negative symptoms of schizophrenia and also has a favorable safety profile. 2. Vanda has utilized pharmacogenetic studies to identify a group of schizophrenic patients that will benefit from this agent that binds to a number of serotonin...
1. DOV 21,947 in a phase Ib study produced a statistically significant reduction in plasma triglyceride levels, body weight, and Body Mass Index (BMI). 2. This compound is believed to not only manage depression but also impact weight gain. 3. A phase II study of DOV 21,947 is being delayed until the...
1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.
New Potentially Effective Antidepressants to be Marketed by a Potentially Effective Alliance
1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Physician - Director
- Director
- Medical Director